Merck licenses ovarian cancer candidate to AstraZeneca

AstraZeneca secured the rights to develop, produce and commercialize Merck & Co.'s experimental drug MK-1775, which is in midstage trials for ovarian cancer. The deal entitles Merck to $50 million upfront, potential milestone fees and sales royalties. "The compound has demonstrated encouraging clinical efficacy data, and we intend to study it in a range of cancer types where there is a high unmet medical need," said Susan Galbraith, head of AstraZeneca's oncology innovative medicines unit.

View Full Article in:

PharmaTimes (U.K.) · Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Director, Compliance - Health Plan Privacy & Security
Kaiser Permanente
Oakland, CA
Regulatory Counsel
Food and Drug Administration
Silver Spring, MD
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Vice President, Commercial Markets
Meridian Health
Neptune, NJ